Evaluation of Antipsychotic Reduction Efforts in Patients With Dementia in Veterans Health Administration Nursing Homes
Publication: American Journal of Psychiatry
CME has expired
Abstract
Objective:
The Veterans Health Administration (VHA) and the Centers for Medicare and Medicaid Services (CMS) each created initiatives to reduce off-label use of antipsychotics in patients with dementia in nursing homes. Although CMS has reported antipsychotic reductions, the impact on prescribing of antipsychotic and other CNS-active medications in the VHA remains unclear. The authors evaluated national trends in antipsychotic and other CNS-active medication prescribing for nursing home patients with dementia in the VHA.
Methods:
The study sample was all veterans with dementia residing in VHA nursing homes for more than 30 days (N=35,742). Using an interrupted time-series design, the quarterly prevalences of antipsychotic, antidepressant, antiepileptic, anxiolytic, opioid, and memory medication prescribing were evaluated from FY2009 through FY2018.
Results:
Antipsychotic prescribing in VHA nursing homes declined from FY2009 to FY2018 (from 33.7% to 27.5%), with similar declines in anxiolytic prescribing (from 33.5% to 27.1%). During this period, prescribing of antiepileptics, antidepressants, and opioids increased significantly (antiepileptics: from 26.8% to 43.3%; antidepressants: from 56.8% to 63.4%; opioids: from 32.6% to 41.2%). Gabapentin served as the main driver of antiepileptic increases (from 11.1% to 23.5%). Increases in antidepressant prescribing included sertraline, mirtazapine, and trazodone. From FY2009 to FY2018, the overall prescribing of non-antipsychotic psychotropic medications grew from 75.0% to 81.1%.
Conclusions:
Antipsychotic and anxiolytic prescribing for VHA nursing home residents with dementia declined, although overall prescribing of other psychotropic and opioid medications increased. Policies focused primarily on reducing antipsychotic use without considering use in the context of other medications may contribute to growth in alternative medication classes with even less evidence of benefit and similar risks.
The U.S. Food and Drug Administration (FDA) has not approved any drugs for behavioral and psychological symptoms of dementia (BPSDs), although the widespread prescribing of psychotropic and opioid medications to persons with dementia could represent off-label attempts to address BPSDs (1–3). Based on mortality concerns, the FDA issued black box warnings for mortality risk associated with atypical antipsychotics (2005) and conventional antipsychotics (2008) when used to treat dementia-related psychosis (4). Given these safety concerns, providers may prescribe alternative CNS-active medications in lieu of antipsychotics. However, commonly used alternatives, such as benzodiazepines and antiepileptics, have even poorer risk-to-benefit ratios (5). Ultimately, among psychotropic medications, atypical antipsychotics have the strongest evidence base for treatment of BPSDs, although their benefits may prove moderate at best (6). Numerous expert bodies and professional organizations, including the American Geriatrics Society, the American Association of Geriatric Psychiatry, and the American Psychiatric Association, have recommended nonpharmacological strategies as first-line treatments for addressing BPSDs (7, 8).
Prior to the first black box warning in 2005, 24%–32% of nursing home residents received antipsychotics (9–11). The Centers for Medicare and Medicaid Services (CMS) launched the National Partnership to Improve Dementia Care in Nursing Homes (CMSNP) in 2012 to address concerns about persistently high rates of antipsychotic use and the quality of care provided to nursing home residents with dementia (12). The CMSNP included training materials and online resources with the goal of reducing antipsychotic prescribing in nursing homes. The CMSNP appeared to lower antipsychotic prescribing in nursing homes from 24% in 2011 to 15% in 2018 (13). Starting in 2015, the CMS Five Star Quality Rating System for nursing homes included a publicly reported measure of antipsychotic drug use by nursing homes through the Nursing Home Compare website, thus incentivizing facilities to reduce their antipsychotic prescribing (14).
Whether the CMSNP recommendations translated into reductions in antipsychotic prescribing within the Veterans Health Administration (VHA), which provides care to many veterans with dementia in VHA nursing homes, named Community Living Centers (CLCs), remains unknown. The VHA maintains over 130 CLCs across the United States, which provide both short- and long-term nursing and medical care for veterans (15). In addition to the potential impact of the CMSNP within the VHA, in December 2013, the VHA launched the Psychotropic Drug Safety Initiative (PDSI), a nationwide psychopharmacology quality improvement initiative. From 2013 through 2017, the PDSI included two targets relevant to veterans with dementia: the proportion for whom antipsychotics were prescribed and the proportion for whom benzodiazepines were prescribed. Further, similar to community nursing homes, CLCs complete the CMS Minimum Data Set 3.0 for clinical assessment of veterans’ health and behaviors as well as to report CMS quality indicators. In 2018, the VHA developed a similar publicly reported rating system adapted from the CMS Nursing Home Compare website, called CLC Compare, to help evaluate the quality of care received by veterans in CLCs (16).
Therefore, both Medicare and the VHA have used antipsychotic use as a proxy measure for quality of care among patients with dementia in nursing home settings (17). In community settings, antipsychotic reduction led to an increase in other types of CNS-active medication prescribing (18); it remains unknown whether this also occurred within the VHA. In this study, we sought to evaluate national trends in antipsychotic and other CNS-active medication prescriptions for veterans with dementia residing in VHA nursing homes as well as to understand how the use of specific agents has changed over time.
Methods
We used patient-level data from the VHA Corporate Data Warehouse (CDW) to evaluate changes in antipsychotic and other CNS-active medication prescriptions from FY2009 through FY2018 for veterans with dementia residing in VHA nursing homes. The Veterans Affairs Ann Arbor Healthcare System institutional review board approved the study.
Study Cohort
We used data from the VHA CDW for all veterans from October 1, 2008, to September 31, 2018 (FY2009–FY2018). We first constructed quarterly cohorts of long-stay residents at VHA nursing facilities (i.e., CLCs). In community settings, “long-stay” is typically defined as a length of stay >100 nursing home days (19). However, only 28.9% of veterans with dementia had a CLC length of stay >100 days. We therefore chose a length of stay >30 days to represent long-stay CLC stays, which represents 53.0% of veterans with dementia in CLCs.
We included a veteran in a given quarterly cohort if they met the long-stay criterion (>30 days) for at least 1 day during the quarter, were ≥65 years of age during the quarter, and had a dementia diagnosis (see Table S1 in the online supplement for ICD-9 and ICD-10 codes) (20). We determined comorbid clinical conditions (e.g., depression, anxiety, bipolar disorder, chronic pain) based on an inpatient or outpatient diagnosis code in the previous 12 months (see Table S1 in the online supplement for ICD-9 and ICD-10 codes for clinical conditions; we identified chronic pain using previously established codes [21, 22]). We excluded veterans with a diagnosis of schizophrenia, Tourette’s syndrome, and Huntington’s disease to match the exclusion criteria that CMS uses for its antipsychotic quality measure (i.e., for Nursing Home Compare and the CMSNP) (23). A long-stay CLC resident remained in the cohort (denominator) until death, the end of the long-stay period (i.e., discharge from CLC), or the end of the study period, whichever came first.
Outcomes
We used Bar-Code Medication Administration data within CDW to identify medications of interest. For each veteran, we determined quarterly CNS-active medication administration, including antipsychotics, antidepressants, antiepileptics, anxiolytics (including benzodiazepines and sedative-hypnotics), opioids, and memory medications (i.e., cholinesterase inhibitors and memantine; see Table S2 in the online supplement) (18). Additionally, we included a composite measure of any non-antipsychotic psychotropic medication use, which included the following medication classes: antidepressants, antiepileptics, and anxiolytics, along with non-antipsychotic CNS-active medication polypharmacy, defined as three or more medications from these classes and/or opioids during a 30-day rolling window.
Statistical Analysis
We used an interrupted time-series design to evaluate quarterly trends in prescribing rates from FY2009 to FY2018. We began the analysis in FY2009, following the FDA black box warnings related to antipsychotic use among patients with dementia. To examine the association of the CMSNP and VHA PDSI recommendations with CNS-active medication prescribing, we divided time into three periods: period 1 covered the interval from FY2009 to the CMSNP (2012, first quarter [Q1]); period 2 covered the interval after the CMSNP (2012 Q2) to before the VHA PDSI (2013 Q3); and period 3 covered the interval from the VHA PDSI (2013 Q4) to the end of the study period (2018 Q4).
We calculated prescribing rates as the percentage of long-stay CLC residents with dementia in each quarter with a prescription of interest. We then fitted a three-phase interrupted time-series regression model to evaluate the association of the CMSNP and VHA PDSI, controlling for autocorrelation by assuming a first-order autoregressive process. We used quarterly percentage prescribed antipsychotics or other medications as our outcome of interest. Models included a linear time-trend variable, indicators for post-CMSNP and post-VHA PDSI, and terms for change in the linear time trend between the study periods (e.g., between the pre- and post-CMSNP periods). Lastly, we evaluated which specific medications increased or decreased over time by computing and plotting the percentage of veterans who had prescriptions for medication during each quarter. We determined statistical significance at the 0.05 level using two-tailed tests, and we used R, version 4.0.2, for all analyses.
Results
Our cohort included 35,742 veterans with who met the long-stay criterion (>30 days) in a CLC between FY2009 and FY2018 (Table 1). The cohort was predominantly male (97.9%) and non-Hispanic White (74.5%) and had a mean age of 80.5 years.
| Characteristic | Overall (N=35,742) | Period 1 (Q4 of 2008 to Q1 of 2012) (N=14,730) | Period 2 (Q2 of 2012 to Q3 of 2013) (N=8,362) | Period 3 (Q4 of 2013 to Q3 of 2018) (N=20,125) | ||||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Age at CLC entry (years) | 80.5 | 8.7 | 81.0 | 7.8 | 80.0 | 8.9 | 79.8 | 9.3 |
| Age at end of study period or death (years) | 82.6 | 8.4 | 84.0 | 7.4 | 83.3 | 8.4 | 81.8 | 8.9 |
| N | % | N | % | N | % | N | % | |
| Sex | ||||||||
| Male | 34,977 | 97.9 | 14,378 | 97.6 | 8,160 | 97.6 | 19,719 | 98.0 |
| Female | 765 | 2.1 | 352 | 2.4 | 202 | 2.4 | 406 | 2.0 |
| Race/ethnicity | ||||||||
| White | 26,641 | 74.5 | 11,038 | 74.9 | 6,242 | 74.6 | 14,889 | 74.0 |
| Black | 5,533 | 15.5 | 2,032 | 13.8 | 1,259 | 15.1 | 3,396 | 16.9 |
| Hispanic | 1,855 | 5.2 | 684 | 4.6 | 386 | 4.6 | 1,105 | 5.5 |
| Other | 3,568 | 10.0 | 1,660 | 11.3 | 861 | 10.3 | 1,840 | 9.1 |
| Clinical conditionsb | ||||||||
| Anxiety | 8,653 | 24.2 | 2,814 | 19.1 | 1,985 | 23.7 | 5,754 | 28.6 |
| Depression | 4,976 | 13.9 | 1,045 | 7.1 | 703 | 8.4 | 3,867 | 19.2 |
| Bipolar disorder | 889 | 2.5 | 346 | 2.3 | 206 | 2.5 | 546 | 2.7 |
| Chronic pain | 24,889 | 69.6 | 9,361 | 63.6 | 5,566 | 66.6 | 14,777 | 73.4 |
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Charlson comorbidity index | 3.3 | 2.7 | 3.0 | 2.5 | 3.0 | 2.5 | 3.4 | 2.7 |
a
Presence determined based on the 30-day period required to establish the patient as a long-stay CLC resident. The sum of veterans across all three study periods yields a number larger than the overall study sample because veterans could be included in more than one time period. Q1–Q4=first through fourth quarters.
b
Diagnoses were based on all inpatient and outpatient visits that occurred during 1 year prior to the CLC admission date.
CNS-Active Medication Prescribing
Figure 1 illustrates the quarterly rates of CNS-active or memory medication prescribing for veterans with dementia residing in CLCs throughout the three study periods (Table S3 in the online supplement presents the quarterly rates represented in Figure 1). Table 2 depicts changes in the level and slope of medication prescribing before and after the start of the CMSNP and VHA PDSI.
FIGURE 1. Antipsychotic, antiepileptic, and other CNS-active medication prescribing among long-stay Community Living Center veterans with dementia, FY2009–FY2018a
aNon-antipsychotic psychotropics include prescriptions for antianxiety, antidepressant, or antiepileptic medications. CMSNP=Centers for Medicare and Medicaid Services National Partnership to Improve Dementia Care in Nursing Homes; VHA PDSI=Veterans Health Administration Psychotropic Drug Safety Initiative.
| Period 1 (Q4 of 2008 to Q1 of 2012) | Period 2 (Q2 of 2012 to Q3 of 2013) | Period 3 (Q4 of 2013 to Q3 of 2018) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medication Class | Usea (%) | Slope (%) | 95% CI | Usea (%) | Slope (%) | 95% CI | Slope Change (%) | 95% CI | Usea (%) | Slope (%) | 95% CI | Slope Change (%) | 95% CI |
| Antipsychotic | 33.7 | 0.06 | −0.03, 0.15 | 32.3 | −0.15 | −0.52, 0.21 | −0.21 | −0.60, 0.18 | 31.4 | −0.13*** | −0.20, −0.06 | 0.03 | −0.31, 0.37 |
| Antiepileptic | 26.8 | 0.11* | 0.02, 0.20 | 31.4 | 0.38** | 0.11, 0.66 | 0.28* | 0.02, 0.53 | 34.1 | 0.39*** | 0.25, 0.54 | 0.01 | −0.21, 0.23 |
| Antidepressant | 56.8 | 0.05 | −0.02, 0.12 | 58.4 | 0.22 | −0.00, 0.44 | 0.17 | −0.07, 0.40 | 58.8 | 0.07* | 0.00, 0.14 | −0.15 | −0.39, 0.10 |
| Anxiolytic | 33.5 | −0.06 | −0.16, 0.04 | 32.7 | 0.05 | −0.25, 0.35 | 0.11 | −0.20, 0.42 | 33.0 | −0.41*** | −0.59, −0.23 | −0.46** | −0.78, −0.14 |
| Non-antipsychotic psychotropic | 75.0 | 0.06 | −0.03, 0.14 | 77.2 | 0.06 | −0.20, 0.32 | 0.00 | −0.28, 0.29 | 77.8 | 0.11** | 0.04, 0.17 | 0.05 | −0.24, 0.33 |
| Opioids | 32.6 | 0.19** | 0.05, 0.33 | 39.3 | 0.63** | 0.20, 1.06 | 0.44* | 0.03, 0.85 | 48.0 | −0.26*** | −0.36, −0.17 | −0.89*** | −1.37, −0.41 |
| Memory medications | 32.4 | −0.33** | −0.52, −0.14 | 25.5 | −0.17 | −0.48, 0.13 | 0.16 | −0.13, 0.44 | 22.8 | −0.05 | −0.11, 0.00 | 0.12 | −0.17, 0.41 |
| CNS polypharmacy | 32.1 | 0.17** | 0.04, 0.30 | 39.4 | 0.52** | 0.18, 0.87 | 0.35* | 0.01, 0.69 | 44.6 | −0.12*** | −0.18, −0.06 | −0.64*** | −1.00, −0.29 |
a
Use reflects the first quarter of each period of interest. For example, in the first quarter of period 1, 33.7% of long-stay veterans with dementia had prescriptions for an antipsychotic, and the estimated quarterly rate of change (i.e., slope) was 0.06 percentage points (95% CI=−0.03, 0.15); by the first quarter of period 2, the prevalence of antipsychotic prescriptions was 32.3%, and during period 2 the estimated quarterly rate of change was −0.15 percentage points (95% CI=−0.52, 0.21). From period 1 to period 2, the quarterly rate of change decreased by −0.21 percentage points (95% CI=−0.60, 0.18).
*<0.05. **<0.01. ***<0.001.
Antipsychotics
At the start of the study (period 1) in FY2009, 33.7% of veterans had an antipsychotic medication prescription. By the end of the study (period 3), antipsychotic prescribing had decreased to 27.5%, representing a 6.2% absolute change from FY2009 to FY2018 (Figure 1A; see also Table S3 in the online supplement). The rate of antipsychotic prescribing decreased across all study periods, but only significantly declined following the start of the VA PDSI (slope=−0.13, p<0.001).
Quetiapine was the most commonly prescribed antipsychotic in all quarters, followed by haloperidol, risperidone, and olanzapine (Figure 2A). Prescribing of most antipsychotic agents remained stable, with the largest declines observed for risperidone (a decline from 9.9% to 6.5%) and haloperidol (a decline from 9.0% to 7.6%).
FIGURE 2. The antipsychotics, antiepileptics, and antidepressants most commonly prescribed for long-stay Community Living Center veterans with dementia, FY2009–FY2018a
aCMSNP=Centers for Medicare and Medicaid Services National Partnership to Improve Dementia Care in Nursing Homes; VHA PDSI=Veterans Health Administration Psychotropic Drug Safety Initiative.
Antiepileptics
Among non-antipsychotic medications, antiepileptics showed the greatest growth in prescribing over the study period (Figure 1A). Among veterans with dementia, antiepileptic use increased from 26.8% at the beginning of the study to 43.3% by the end of period 3, representing a 16.5% absolute change. Antiepileptic prescribing increased significantly during period 1 (i.e., before the start of the CMSNP; slope=0.11, p=0.02) and continued to increase following the start of the CMSNP (period 2; slope change=0.28, p=0.03). Following the start of the VHA PDSI, antiepileptic prescribing continued to increase at a similar rate.
Prescribing of gabapentin, valproate derivatives, and levetiracetam had the largest increases during the study period (Figure 2B). The most prescribed antiepileptic was gabapentin, for which prescribing grew from 11.1% to 23.5% during the study period.
Antidepressants
Antidepressants were the most commonly prescribed CNS-active medication class at all study time points (Figure 1B). Overall use increased from 56.8% at the start of period 1 to 63.4% at the end of period 3 (6.6% increase). The rate of antidepressant growth was highest in period 3, after the start of the VHA PDSI (slope=0.07, p=0.04) (Table 2). By the post-VHA PDSI period, sertraline was the most commonly prescribed antidepressant among our study population (Figure 2C). Use of sedating antidepressants such as mirtazapine (from 10.2% to 14.5%) and trazodone (from 14.4% to 17.5%) increased, while citalopram declined markedly.
Anxiolytics
Anxiolytic prescribing (including benzodiazepines) declined throughout the study period, decreasing from 33.5% at the start of period 1 to 27.1% at the end of the study. The greatest decline in anxiolytic prescribing was observed in period 3 after the start of the VHA PDSI (slope change=−0.46, p=0.006).
Opioids
Prescription of opioids appeared common among long-stay veterans with dementia and increased significantly during period 1 (from 32.6% to 39.1%; slope=0.19, p=0.008) and period 2 (from 39.3% to 46.0%; slope change=0.44, p=0.04). After the start of period 3 (VHA PSDI), opioid prescribing began to decrease significantly, from 48.0% to 41.2% at the end of the study (slope change=−0.89, p<0.001).
Memory Medications
Prescribing of memory medications declined throughout the study, from 32.4% at the start of period 1 to 21.8% at the end of period 3, representing a 10.6% absolute decline. Memory medications were the least prescribed medication class for veterans with dementia throughout the study period.
Non-Antipsychotic Psychotropic Prescribing Overall and CNS-Active Polypharmacy
The prescribing of non-antipsychotic psychotropic medication overall (i.e., antiepileptics, antidepressants, and anxiolytics) increased in period 1, steadied following the start of the CMSNP in period 2, and increased significantly in period 3, following the VHA PDSI (Figure 1B; Table 2). A total of 81.1% of long-stay veterans had prescriptions for a non-antipsychotic psychotropic at the end of the study period (increased from 75.0% at the start of period 1). Prescribing of non-antipsychotic CNS-active polypharmacy (i.e., three or more non-antipsychotic prescriptions for antidepressants, antiepileptics, anxiolytics, and opioids) increased during the first and second periods but declined during the third period, following the VHA PDSI (Table 2; see also Figure S2 in the online supplement). Prescribing of CNS-active polypharmacy overall increased from 32.1% at the start of period 1 to 41.3% at the end of period 3, representing an absolute increase of 9.2 percentage points.
Discussion
This study provides data on national trends in CNS-active medication prescribing for veterans with dementia in VHA CLCs. We found that antipsychotic use among veterans with dementia declined over time, and the decline was most significant following the VHA PDSI. Antidepressant prescribing increased following the VHA PDSI while antiepileptic prescribing increased following both the CMSNP and the VHA PDSI. Overall prescribing of non-antipsychotic psychotropic medications in VHA CLCs remained high, with over 80% of veterans with dementia receiving prescriptions for a non-antipsychotic psychotropic medication at the end of the study period. Gabapentin, valproate derivatives, and sedative antidepressants had the largest contributions to the growth in CNS-active medication prescribing. Anxiolytic prescribing declined following the VHA PDSI, and memory medication prescribing declined across all study periods and had a lower prescribing rate than any of the other medication classes observed. Lastly, opioid prescribing remained common and increasing prior to and during the CMSNP, only decreasing following the start of the VHA PDSI.
Our findings in the VHA are consistent with previous studies in non-VHA settings (one in the community, two in nursing homes) (2, 18, 24), which found that initiatives focused on reducing antipsychotic use may have contributed to providers shifting to alternative medication classes with similar risks and even less evidence of benefit. A Canadian study (24) showed that decreased antipsychotic use in nursing homes between 2004 and 2013 was offset by increased sedative antidepressant and antiepileptic use. A recent U.S. study examining Medicare beneficiaries found that antiepileptic prescriptions for nursing home residents increased and accelerated after the initiation of the CMSNP (18). It appears that these trends also extend to the VHA CLC population, where antiepileptic prescribing occurred at even higher rates compared with rates outside of the VHA.
When evaluating change in specific medications, we found that quetiapine was the most commonly prescribed antipsychotic among patients with dementia, consistent with findings from community long-term care populations (25). While quetiapine has been found to have a lower mortality risk in dementia (26), studies also suggest that it may have less evidence of benefit in reducing BPSDs (27). Increases in antidepressant use were largely driven by prescribing of sertraline and sedating antidepressants (e.g., trazodone and mirtazapine), which may be used for treatment of depression or BPSDs. Notable decreases in citalopram were observed following the 2011 FDA drug safety warning regarding concerns about QT prolongation with high-dose citalopram use, as has been reported in other studies (28, 29).
The growth of antiepileptic use was largely driven by gabapentin, for which prescribing doubled during the study period, likely off-label for pain, anxiety, or BPSDs, rather than for seizure disorders (25). Significant increases in prescription opioid use were observed before and during the CMSNP. This is consistent with studies demonstrating high rates of opioid prescribing for patients with dementia in the community (2) as well as population-based studies demonstrating significant growth in opioid prescribing for patients with dementia (3). While such treatment may reflect improved recognition and treatment of pain in dementia or palliative approaches to dementia end-of-life care, it may also reflect another attempt to reduce BPSDs (3, 30). In addition to measures of the percentage of long-stay residents with dementia for whom an antipsychotic is prescribed, VHA CLCs also have a publicly reported quality measure of percentage of long-stay CLC residents who self-report moderate or severe pain (16), further incentivizing treatment of pain.
A recent international panel of geriatric psychiatry and dementia care experts noted that antipsychotics are the most effective pharmacotherapy for BPSDs, including psychosis, agitation, and aggression (31). Studies reviewing the use of other medication classes, such as antidepressants, benzodiazepines, antiepileptics, and opioids, for treatment of BPSDs show minimal benefit in reducing such symptoms (5, 30, 32). Additionally, these alternative medication classes substituted for antipsychotics can yield significant risks. Benzodiazepines can contribute to falls, worsened cognition, respiratory depression, and paradoxical disinhibition (33). Antiepileptics such as valproate derivatives can cause gait disturbances, tremor, cognitive changes, and mortality (26, 34). Gabapentin use can lead to ataxia, dizziness, drowsiness, fatigue, falls, and increased risk of respiratory suppression when combined with opioids (35). Reductions in prescribing of memory medications may reflect provider concerns about limited therapeutic benefit for patients with advanced dementia as well as concerns regarding side effects, including nausea, loss of appetite, and diarrhea (36).
The VHA may have achieved declines in several classes of CNS-active medications as a result of its multipronged efforts. In contrast with the CMSNP, which focused on antipsychotic use only, the VHA PDSI, in addition to an antipsychotic prescribing measure, addresses benzodiazepine use, which may explain the observed anxiolytic reductions in the VHA. Further VHA initiatives, including the 2013 Opioid Safety Initiative, may explain reductions in opioid prescribing as well as increased recognition of the dangers of opioid prescribing in patients with dementia (37). Additionally, in 2010, the VHA launched an initiative to adapt an evidenced-based behavioral approach (Staff Training in Assisted Living Residences, or STAR [38]) for the VHA to increase uptake of nonpharmacological strategies for BPSDs. We do not know whether CLCs with STAR implementation decreased antipsychotic use, and if so, whether the decrease reflected increased use of nonpharmacological strategies (39). Reports from long-term care staff outside of the VHA suggest considerable challenges in implementing such interventions given staff turnover as well as the time and resources needed to implement nonpharmacological strategies (40).
Our study has several limitations. First, our results on prescription rates may not be directly comparable to those in community nursing homes given the differences in the structure of VHA CLCs, including the presence of a national formulary and the range of psychosocial services available to veterans (15). Next, our sample includes a high proportion of men, and our study results may not generalize to other clinical populations. Third, prescriptions filled from pharmacy data can be an imprecise measure of actual drug exposure; medication fills may not reflect day-to-day use. However, this study focused on the impact of initiatives that influence prescribing rather than medication use. Next, we do not know the indication for medication prescribing (e.g., gabapentin could be prescribed for pain, seizures, or BPSDs) or the appropriateness of such prescribing. However, the potential for medication-related harms remains regardless of clinical indication. Further, prescribing trends may reflect changes in patient characteristics over time; however, our approach is consistent with the CMSNP and VHA PDSI, neither of which use case-mix adjustment. Lastly, administrative data do not include reliable measures of nonpharmacological interventions, limiting our ability to examine whether increased use of such interventions was associated with declines in antipsychotic prescribing.
Conclusions
Although antipsychotic prescribing to veterans with dementia in VHA nursing homes declined following both the CMSNP and the PDSI, concomitant increases in antiepileptic, antidepressant, and opioid prescribing occurred. Within the VHA, rates of anxiolytic and opioid prescribing to veterans with dementia declined following the PDSI, but the rate of any non-antipsychotic psychotropic use overall increased. Initiatives focused on improving quality of care for nursing home residents with BPSDs both in the VHA and in the community should 1) monitor use of all CNS-active medication and other potentially sedating treatments used for sedation in dementia; and 2) consider how to incentivize and measure use of recommended evidence-based nonpharmacological alternatives (6, 7). The latter link to policy changes to stimulate a reorganization of dementia care, where providers are compensated for time spent in elucidating and addressing modifiable triggers to BPSDs, and not perversely incentivized to utilize other medications with even less evidence for benefit in dementia.
Supplementary Material
File (appi.ajp.21060591.ds001.pdf)
- View/Download
- 225.99 KB
References
1.
Maust DT, Langa KM, Blow FC, et al: Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. Int J Geriatr Psychiatry 2017; 32:164–174
2.
Maust DT, Strominger J, Bynum JPW, et al: Prevalence of psychotropic and opioid prescription fills among community-dwelling older adults with dementia in the US. JAMA 2020; 324:706–708
3.
Jensen-Dahm C, Christensen AN, Gasse C, et al: The use of opioids and antipsychotics in elderly with dementia: have opioids replaced antipsychotics in treating behavioral symptoms in dementia? J Alzheimers Dis 2020; 73:259–267
4.
FDA Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. US Food and Drug Administration. 2005. http://www.psychrights.org/drugs/FDAantipsychotics4elderlywarning.htm
5.
Gerlach LB, Kales HC: Pharmacological management of neuropsychiatric symptoms of dementia. Curr Treat Options Psych 2020; 7:489–507
6.
Kales HC, Gitlin LN, Lyketsos CG: Assessment and management of behavioral and psychological symptoms of dementia. BMJ 2015; 350:h369
7.
American Geriatrics Society, American Association of Geriatric Psychiatry: Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003; 51:1287–1298
8.
Choosing Wisely: American Psychiatric Association: Five things physicians and patients should question. September 20, 2013. https://www.choosingwisely.org/societies/american-psychiatric-association/
9.
Chen Y, Briesacher BA, Field TS, et al: Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010; 170:89–95
10.
Feng Z, Hirdes JP, Smith TF, et al: Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. Int J Geriat Psychiatry 2009; 24:1110–1118
11.
Kamble P, Chen H, Sherer J, et al: Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother 2008; 6:187–197
12.
Centers for Medicare and Medicaid Services: CMS announces partnership to improve dementia care in nursing homes. 2012. https://www.cms.gov/newsroom/press-releases/cms-announces-partnership-improve-dementia-care-nursing-homes
13.
US Government Accountability Office: Antipsychotic drug use: HHS has initiatives to reduce use among older adults in nursing homes, but should expand efforts to other settings. January 2015. https://www.gao.gov/assets/gao-15-211.pdf
14.
Centers for Medicare and Medicaid Services: Five Star Quality Rating System. 2019. https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandComplianc/FSQRS.html
15.
Thomas KS, Cote D, Makineni R, et al: Change in VA Community Living Centers 2004–2011: shifting long-term care to the community. J Aging Soc Policy 2018; 30:93–108
16.
US Department of Veterans Affairs: Quality of care: Community Living Center health surveys. 2015. https://www.va.gov/QUALITYOFCARE/apps/aspire/clcsurvey.aspx
17.
Rubin HR, Pronovost P, Diette GB: Methodology Matters: From a process of care to a measure: the development and testing of a quality indicator. Int J Qual Health Care 2001; 13:489–496
18.
Maust DT, Kim HM, Chiang C, et al: Association of the Centers for Medicare and Medicaid Services’ national partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014. JAMA Intern Med 2018; 178:640–647
19.
Yun H, Kilgore ML, Curtis JR, et al: Identifying types of nursing facility stays using Medicare claims data: an algorithm and validation. Health Serv Outcomes Res Methodol 2010; 10:100–110
20.
Taylor DH, Jr., Fillenbaum GG, Ezell ME: The accuracy of Medicare claims data in identifying Alzheimer’s disease. J Clin Epidemiol 2002; 55:929–937
21.
Maust DT, Kim HM, Wiechers IR, et al: Benzodiazepine use among Medicare, commercially insured, and veteran older adults, 2013–2017. J Am Geriatr Soc 2021; 69:98–105
22.
Ilgen MA, Kleinberg F, Ignacio RV, et al: Noncancer pain conditions and risk of suicide. JAMA Psychiatry 2013; 70:692–697
23.
Centers for Medicare and Medicaid Services: MDS 3.0 Quality Measures User’s Manual. 2020. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/NHQIQualityMeasures
24.
Vasudev A, Shariff SZ, Liu K, et al: Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004–2013. Am J Geriatr Psychiatry 2015; 23:1259–1269
25.
Gerlach LB, Kales HC, Kim HM, et al: Trends in antipsychotic and mood stabilizer prescribing in long-term care in the US: 2011–2014. J Am Med Directors Assoc 2020; 21:1629–1635
26.
Kales HC, Kim HM, Zivin K, et al: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169:71–79
27.
Huybrechts KF, Gerhard T, Crystal S, et al: Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344:e977
28.
Gerlach LB, Kales HC, Maust DT, et al: Unintended consequences of adjusting citalopram prescriptions following the 2011 FDA warning. Am J Geriatr Psychiatry 2017; 25:407–414
29.
Gerlach LB, Kim HM, Yosef M, et al: Assessing responsiveness of health systems to drug safety warnings. Am J Geriatr Psychiatry 2018; 26:476–483
30.
Brown R, Howard R, Candy B, et al: Opioids for agitation in dementia. Cochrane Database Syst Rev 2015; (5):CD009705
31.
Kales HC, Lyketsos CG, Miller EM, et al: Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr 2018; 31:83–90
32.
Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293:596–608
33.
Peisah C, Chan DKY, McKay R, et al: Practical guidelines for the acute emergency sedation of the severely agitated older patient. Intern Med J 2011; 41:651–657
34.
Maust DT, Kim HM, Seyfried LS, et al: Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015; 72:438–445
35.
US Food and Drug Administration. Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug Safety Communication: Serious Breathing Problems. December 19, 2019. https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication
36.
Renn BN, Asghar-Ali AA, Thielke S, et al: A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. Am J Geriatr Psychiatry 2018; 26:134–147
37.
Sandbrink F, Oliva EM, McMullen TL, et al: Opioid prescribing and opioid risk mitigation strategies in the Veterans Health Administration. J Gen Intern Med 2020; 35:927–934
38.
Teri L, Huda P, Gibbons L, et al: STAR: a dementia-specific training program for staff in assisted living residences. Gerontologist 2005; 45:686–693
39.
Karel MJ, Teri L, McConnell E, et al: Effectiveness of expanded implementation of STAR-VA for managing dementia-related behaviors among veterans. Gerontologist 2016; 56:126–134
40.
Simmons SF, Bonnett KR, Hollingsworth E, et al: Reducing antipsychotic medication use in nursing homes: a qualitative study of nursing staff perceptions. Gerontologist 2017; 58:e239–e250
Information & Authors
Information
Published In
History
Received: 9 June 2021
Revision received: 12 November 2021
Accepted: 1 February 2022
Published online: 26 May 2022
Published in print: August 2022
Keywords
Authors
Funding Information
Supported by a VA Health Services Research and Development award (VA IIR 15-330; Dr. Zivin). Dr. Gerlach was supported in part by National Institute on Aging grant K23AG066864.The authors report no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).